Logo image of LUMO

LUMOS PHARMA INC (LUMO) Stock Fundamental Analysis

USA - NASDAQ:LUMO - US55028X1090 - Common Stock

4.34 USD
0 (0%)
Last: 12/11/2024, 8:00:00 PM
4.34 USD
0 (0%)
After Hours: 12/11/2024, 8:00:00 PM
Fundamental Rating

3

LUMO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. While LUMO seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, LUMO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LUMO had negative earnings in the past year.
In the past year LUMO has reported a negative cash flow from operations.
In the past 5 years LUMO always reported negative net income.
LUMO had a negative operating cash flow in each of the past 5 years.
LUMO Yearly Net Income VS EBIT VS OCF VS FCFLUMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -199.97%, LUMO is doing worse than 90.44% of the companies in the same industry.
LUMO's Return On Equity of -710.54% is on the low side compared to the rest of the industry. LUMO is outperformed by 81.95% of its industry peers.
Industry RankSector Rank
ROA -199.97%
ROE -710.54%
ROIC N/A
ROA(3y)-52.36%
ROA(5y)-41.28%
ROE(3y)-70.33%
ROE(5y)-54.18%
ROIC(3y)N/A
ROIC(5y)N/A
LUMO Yearly ROA, ROE, ROICLUMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

LUMO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LUMO Yearly Profit, Operating, Gross MarginsLUMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

LUMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LUMO has been reduced compared to 1 year ago.
The number of shares outstanding for LUMO has been increased compared to 5 years ago.
LUMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LUMO Yearly Shares OutstandingLUMO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
LUMO Yearly Total Debt VS Total AssetsLUMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -19.20, we must say that LUMO is in the distress zone and has some risk of bankruptcy.
LUMO has a worse Altman-Z score (-19.20) than 86.02% of its industry peers.
There is no outstanding debt for LUMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.2
ROIC/WACCN/A
WACC11.91%
LUMO Yearly LT Debt VS Equity VS FCFLUMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

LUMO has a Current Ratio of 2.66. This indicates that LUMO is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.66, LUMO is not doing good in the industry: 69.38% of the companies in the same industry are doing better.
A Quick Ratio of 2.66 indicates that LUMO has no problem at all paying its short term obligations.
The Quick ratio of LUMO (2.66) is worse than 67.79% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
LUMO Yearly Current Assets VS Current LiabilitesLUMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for LUMO have decreased by -6.98% in the last year.
LUMO shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.71%.
The Revenue for LUMO have been decreasing by -30.34% on average. This is quite bad
EPS 1Y (TTM)-6.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.46%
Revenue 1Y (TTM)29.71%
Revenue growth 3Y117.26%
Revenue growth 5Y-30.34%
Sales Q2Q%10271.43%

3.2 Future

Based on estimates for the next years, LUMO will show a very strong growth in Earnings Per Share. The EPS will grow by 40.16% on average per year.
The Revenue is expected to grow by 53.11% on average over the next years. This is a very strong growth
EPS Next Y8.71%
EPS Next 2Y21.42%
EPS Next 3Y18.96%
EPS Next 5Y40.16%
Revenue Next Year385.58%
Revenue Next 2Y-14.99%
Revenue Next 3Y112.7%
Revenue Next 5Y53.11%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LUMO Yearly Revenue VS EstimatesLUMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 200M 400M 600M
LUMO Yearly EPS VS EstimatesLUMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 10 -10 20 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LUMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUMO Price Earnings VS Forward Price EarningsLUMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUMO Per share dataLUMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as LUMO's earnings are expected to grow with 18.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.42%
EPS Next 3Y18.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LUMO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUMOS PHARMA INC

NASDAQ:LUMO (12/11/2024, 8:00:00 PM)

After market: 4.34 0 (0%)

4.34

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/dmh
Earnings (Next)N/A N/A
Inst Owners25.37%
Inst Owner Change0%
Ins Owners14.94%
Ins Owner Change0%
Market Cap37.54M
Analysts78
Price Target9.88 (127.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.49%
Min EPS beat(2)-15.49%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-15.49%
Max EPS beat(4)26.47%
EPS beat(8)5
Avg EPS beat(8)4.45%
EPS beat(12)8
Avg EPS beat(12)7.15%
EPS beat(16)11
Avg EPS beat(16)9.56%
Revenue beat(2)2
Avg Revenue beat(2)147.42%
Min Revenue beat(2)43.53%
Max Revenue beat(2)251.32%
Revenue beat(4)3
Avg Revenue beat(4)11605.7%
Min Revenue beat(4)-46.54%
Max Revenue beat(4)46174.5%
Revenue beat(8)6
Avg Revenue beat(8)5867.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-52.97%
PT rev (3m)-55.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.85%
EPS NY rev (1m)0.4%
EPS NY rev (3m)-4.9%
Revenue NQ rev (1m)-91.21%
Revenue NQ rev (3m)-94.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.03
P/FCF N/A
P/OCF N/A
P/B 7.64
P/tB 7.64
EV/EBITDA N/A
EPS(TTM)-4.29
EYN/A
EPS(NY)-2.2
Fwd EYN/A
FCF(TTM)-3.66
FCFYN/A
OCF(TTM)-3.66
OCFYN/A
SpS0.25
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -199.97%
ROE -710.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.36%
ROA(5y)-41.28%
ROE(3y)-70.33%
ROE(5y)-54.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z -19.2
F-Score4
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0%
Cap/Sales(5y)0%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.46%
EPS Next Y8.71%
EPS Next 2Y21.42%
EPS Next 3Y18.96%
EPS Next 5Y40.16%
Revenue 1Y (TTM)29.71%
Revenue growth 3Y117.26%
Revenue growth 5Y-30.34%
Sales Q2Q%10271.43%
Revenue Next Year385.58%
Revenue Next 2Y-14.99%
Revenue Next 3Y112.7%
Revenue Next 5Y53.11%
EBIT growth 1Y-2.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.08%
OCF growth 3YN/A
OCF growth 5YN/A